females, the majority of which were treated hypretensives. Mean age was 58Ϯ17 years. Thirty three subjects were diabetic, 75 non-dippers.
Objective: Recent evidence suggests that pulse pressure (PP) is an independent predictor of cardiovascular risk. The objective of this study is to compare mean values and reproducibility of PP obtained by measuring blood pressure in the clinic (CPP), at home (HPP) and with ambulatory monitoring (APP).
Methods: A total of 393 hypertensive subjects (mean age 51.5Ϯ11.5 [SD] years, 59% men, 35% treated) measured CPP (2 visits), HPP (6 days) and APP (24 hours). The reproducibility of PP was assessed using the SD of differences (SDD) between measurements in 133 untreated subjects who had repeated CPP (5 visits), HPP (6 days) and APP measurements (2 occasions).
Results: There was no difference between mean CPP (51.0Ϯ13.3 mm Hg) and HPP (50.2Ϯ11.0) whereas APP (48.8Ϯ8.4) was lower than both CPP (mean difference 2.3Ϯ10.3 mm Hg, 95%CI 1.2, 3.3, pϽ0.01) and HPP (1.5Ϯ7.8, 95%CI 0.7, 2.3, pϽ0.01). The SDD between repeated measurements was about 10 mm Hg for CPP (1 visit), 5.2 for HPP (2 days) and 4 mm Hg for APP (24-hour). For a parallel comparative trial aiming to detect a difference of 3 mm Hg PP in the effect of two drugs, 415 subjects would be required when using CPP compared to 127 using HPP and 63 using APP.
Conclusions: These data suggest that although differences among mean values of CPP, HPP and APP are small, differences in reproducibility are important and should be taken into account in the design of trials assessing drug effects on PP. Background: Treatment guidelines have been established separately for the management of osteoarthritis (OA) and hypertension, but guidelines do not exist for the management of both conditions simultaneously. In that treatment of one common condition (OA) may exacerbate another common condition (hypertension), the question arises how should clinicians efficiently manage patients in the absence of guidelines.
Objective: To describe how physicians manage clinically significant edema and/or destabilized blood pressure (BP) in OA patients with hypertension, when rofecoxib or celecoxib is initiated.
Methods: A cross-sectional survey was administered to physicians attending arthritis educational programs in the US between June and August 2001.
Results: 828 physicians completed the survey. The most common physician specialties were family practice (FP; 33%), internal medicine (IM; 25%), orthopedics (ORS; 15%), and rheumatology (Rheum; 11%). Physicians expect that most patients will contact them, by telephone or office visit, when they experience edema (68.4%). Physicians often request a follow-up visit for BP monitoring (65.6% of the time) after initiating a COX-2 specific inhibitor. Of the physician specialties, FPs and IMs were most likely to schedule a follow-up visit for BP monitoring, whereas ORS were least likely. The presence of edema and/or destabilized BP generally led to the discontinuation of the COX-2 inhibitor (50-65% of time). IMs and FPs were most likely to treat edema by initiating or modifying diuretic therapy (33-51% of time). For destabilized BP, an antihypertensive was initiated or modified 40-55% of time by FPs/IMs. ORS generally would refer patients to IMs/FPs. Differences in the management of edema and/or destabilized BP were noted depending on which COX-2 inhibitor was prescribed. Physicians were more likely to switch from rofecoxib to celecoxib (23-34% switch to celecoxib from rofecoxib vs 3-4% switch to rofecoxib from celecoxib). Physicians were also more likely to adjust the celecoxib (19-28%) than rofecoxib dose (7-11%).
Conclusions: A significant percentage of physicians reported that they monitor patients with OA and hypertension for destabilized BP and edema following initiation of a COX-2 specific inhibitor. When edema and/or destabilized BP are identified, physicians intervene in most cases (90%). Since managing patients with edema and destabilized BP can be costly, physicians should consider the increased incidence of edema and destabilized BP observed with rofecoxib relative to celecoxib when making treatment decisions.
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